Nexavar News and Research

RSS
Nirogacestat shows promising results in patients with desmoid tumors

Nirogacestat shows promising results in patients with desmoid tumors

Repurposing drugs to outsmart cancers

Repurposing drugs to outsmart cancers

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

China leads in pharma sector patent filings among BRIC Nations

China leads in pharma sector patent filings among BRIC Nations

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences receives U.S. patent for combination cancer therapy

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.